Celcuity’s Revtorpyk Wins FDA Approval as First PI3K/mTOR Drug for PIK3CA-Wild-Type Breast Cancer

원문 링크: WordPress 원문

ENGKOR

Revtorpyk (gedatolisib) is Celcuity’s first approved drug — and the first FDA-approved therapy that blocks both PI3K and mTOR for people with HR-positive, HER2-negative advanced breast cancer who do not have a PIK3CA mutation. Until now, PI3K-targeted drugs like alpelisib and inavolisib were only available to patients whose tumors carried that specific mutation. Revtorpyk opens the PI3K pathway door for the majority who are PIK3CA wild-type.

On July 14, 2026, the FDA approved Revtorpyk in combination with fulvestrant, with or without palbociclib (Ibrance), for adults with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation, following progression on at least one line of endocrine therapy in the metastatic setting.[1]

This article explains what Revtorpyk is, what the VIKTORIA-1 trial showed, what the approval does and does not mean, and why a drug that fills a biomarker gap still comes with important open questions.

If you remember only four things

• Revtorpyk is the first FDA-approved PI3K/mTOR inhibitor for PIK3CA wild-type breast cancer. Previous PI3K drugs required a PIK3CA mutation; Revtorpyk does not.

• In the VIKTORIA-1 trial, adding Revtorpyk to fulvestrant and palbociclib reduced the risk of progression or death by 76% compared to fulvestrant alone (HR 0.24). Median PFS was 9.3 months vs 2.0 months.

• Overall survival data are not yet mature (only 25% of expected deaths). The approval is based on progression-free survival — whether people live longer is still unknown.

• Revtorpyk is an intravenous infusion given weekly , not a pill. It comes with meaningful side effects including stomatitis, skin reactions, and high blood sugar.

What is Revtorpyk, and how is it different?

Revtorpyk (gedatolisib) is a pan-PI3K/mTOR inhibitor. It blocks all four class I PI3K isoforms — alpha, beta, delta, and gamma — plus both mTOR complexes, mTORC1 and mTORC2.[4] This dual blockade is what sets it apart from earlier PI3K drugs.

Generated conceptual mechanism illustration. It simplifies pathway biology and is not a quantitative efficacy figure.

Existing PI3K alpha inhibitors like alpelisib (Piqray) and inavolisib (Itovebi) selectively target the PI3K alpha isoform, which is often mutated in breast cancer. But they only work when a PIK3CA mutation is present — and roughly 60–70% of HR+/HER2- advanced breast cancers are PIK3CA wild-type. Those patients had no PI3K-pathway targeted option until now.

By inhibiting all PI3K isoforms plus mTOR, Revtorpyk can suppress the pathway regardless of PIK3CA mutation status. The FDA approval covers the wild-type population; Celcuity plans to submit a separate application for the PIK3CA-mutant group later in 2026.[7]

Revtorpyk is given as a 30-minute intravenous infusion once weekly (Days 1, 8, and 15 of each 28-day cycle), at a fixed dose of 180 mg.[1] It is not an oral drug.

What did the VIKTORIA-1 trial show?

VIKTORIA-1 was an open-label, randomized Phase 3 trial that enrolled 392 adults with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation. Patients were randomized 1:1:1 to three arms:[1,5]

**Arm: **A (triplet)

**Regimen: **gedatolisib + fulvestrant + palbociclib

**Arm: **B (doublet)

**Regimen: **gedatolisib + fulvestrant

**Arm: **C (control)

**Regimen: **fulvestrant alone

Progression-free survival (primary endpoint):

**Comparison: **Arm A vs C

**Median PFS: **9.3 vs 2.0 months

**HR (95% CI): **0.24 (0.17–0.35)

**p-value: **<0.0001

**Comparison: **Arm B vs C

**Median PFS: **7.4 vs 2.0 months

**HR (95% CI): **0.33 (0.24–0.48)

**p-value: **<0.0001

Original-source crop from Celcuity’s October 18, 2025 VIKTORIA-1 results announcement. It preserves the reported PFS values and the statement that overall survival was immature at that analysis. Tap the image to open the source PDF.

Objective response rate (in patients with measurable disease):

**Arm: **A

**ORR (95% CI): **32% (23–40)

**Arm: **B

**ORR (95% CI): **28% (20–38)

**Arm: **C

**ORR (95% CI): **1% (0–5)

Duration of response:

**Arm: **A

**Median DoR (95% CI): **17.5 months (8.8–NE)

**Arm: **B

**Median DoR (95% CI): **12.0 months (8.1–NE)

The triplet regimen showed the strongest efficacy, with a 76% reduction in the risk of progression or death and a median PFS of 9.3 months. The doublet without palbociclib was also effective, with a 67% risk reduction and 7.4-month median PFS.

The control arm’s median PFS of 2.0 months reflects the limited benefit of fulvestrant alone in this previously treated population — and underscores the unmet need.

What the data do not yet tell us

Overall survival is immature. At the time of the PFS analysis, only 25% of expected deaths had occurred.[1] This means we do not know whether Revtorpyk helps people live longer. The PFS benefit is real and statistically robust, but PFS improvement does not always translate into longer survival.

Cross-trial comparisons are not valid. The 9.3-month median PFS should not be directly compared to PFS numbers from trials of other drugs (alpelisib, inavolisib, elacestrant, capivasertib, etc.). Different trials enrolled different populations with different prior therapies and different PIK3CA mutation requirements.

The label’s discontinuation rate surprised analysts. BioPharma Dive reported that Revtorpyk’s prescribing information showed higher discontinuation rates than what Celcuity had presented at ESMO 2025.[3] Real-world experience will be important to understand how tolerable the weekly IV regimen is outside a clinical trial.

Safety: what to watch for

The FDA label includes warnings for:[1]

• Stomatitis (mouth sores) — a known class effect of mTOR inhibition

• Dermatologic adverse reactions — rash and other skin effects

• Hyperglycemia — elevated blood sugar, another PI3K/mTOR class effect

• Embryo-fetal toxicity — contraindicated in pregnancy

Common adverse reactions in the trial included stomatitis, nausea, fatigue, diarrhea, decreased appetite, and rash. The weekly IV administration also means regular clinic visits, which affects quality of life and access differently than an oral drug would.

Why this matters for patients and the field

For the roughly two-thirds of HR+/HER2- advanced breast cancer patients whose tumors are PIK3CA wild-type, Revtorpyk is the first targeted therapy that addresses the PI3K pathway. Before this approval, the biomarker conversation was essentially: “You have a PIK3CA mutation — you can try a PI3K inhibitor. You don’t — you cannot.” Revtorpyk changes that binary.

The approval also validates a dual PI3K/mTOR inhibition strategy that had been pursued for years without success. Earlier pan-PI3K inhibitors struggled with toxicity; Revtorpyk’s approval suggests a therapeutic window can be found.

However, this is not a cure. The median PFS benefit is measured in months, not years. The IV route means regular hospital visits. And the OS question remains open. For an individual patient, the decision involves weighing these factors against the alternatives — including chemotherapy, other targeted therapies, and clinical trials.

What comes next

Celcuity expects to launch Revtorpyk commercially in late Q3 2026.[3] The company also plans to submit an sNDA in Q3 2026 for the PIK3CA-mutant population, based on a separate cohort of VIKTORIA-1.[7]

Key things to watch:

– Overall survival data — when will the OS analysis mature, and what will it show?

– Real-world tolerability — will discontinuation rates in practice match or exceed the label?

– PIK3CA-mutant approval — how will Revtorpyk compete with established PI3Kα inhibitors in the mutant setting?

– Sequencing and combinations — where does a weekly IV pan-PI3K/mTOR inhibitor fit among oral SERDs, oral PI3Kα inhibitors, ADCs, and chemotherapy?

Bottom line

Revtorpyk is the first FDA-approved drug that blocks PI3K and mTOR for people with PIK3CA wild-type HR+/HER2- advanced breast cancer — a population that previously had no PI3K-pathway targeted option. The VIKTORIA-1 trial showed a clear PFS benefit, but overall survival data are not yet mature, and the IV route plus side effect profile mean this is a meaningful option, not a universal solution.

References

• FDA. “FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer.” July 14, 2026. FDA approval notice

• FDA. Revtorpyk (gedatolisib) prescribing information. Drugs@FDA. Drugs@FDA

• Alvarado D. “Celcuity gains FDA approval for closely watched breast cancer drug.” BioPharma Dive. July 15, 2026. BioPharma Dive

• Celcuity Inc. “Celcuity Announces FDA Approval of REVTORPYK (gedatolisib).” Globe Newswire. July 14, 2026. Celcuity announcement

• ClinicalTrials.gov. “VIKTORIA-1 (NCT05501886).” ClinicalTrials.gov: NCT05501886

• Reuters. “US FDA approves Celcuity’s breast cancer drug.” July 14, 2026. Reuters

• Drugs.com. “FDA Approves Revtorpyk (gedatolisib) for HR+/HER2- PIK3CA Wild-Type Breast Cancer.” July 2026. Drugs.com

This article is for scientific and educational information only. It is not medical advice or investment advice. Treatment decisions should be discussed with qualified healthcare professionals.